Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M

Core View - The company is on track to achieve an adjusted EBITDA greater than $135 million for FY25, indicating strong financial performance and cash flow management [1] Financial Performance - The company reported significant progress in maximizing LINZESS, with sustained profits and cash flows aimed at strengthening its financial position and maintaining compliance with debt covenants [1] - As of the end of Q4, the company had over $200 million in cash and cash equivalents, reflecting a solid liquidity position [1] Sales and Revenue Guidance - The company is on track to meet the low-end of its full-year LINZESS U.S. net sales and total revenue guidance ranges for 2025 [1] Clinical Development - The company met with the FDA to align on a confirmatory Phase 3 trial design for apraglutide, targeting treatment for short bowel syndrome with intestinal failure [1] - A confirmatory trial is expected to be initiated in the first half of 2026, with further details to be provided in the upcoming Q4 and full-year 2025 update [1]